GLG News by Biotechnology Patent Experts: Lawyers (US)

* As noted in the Wall Street Journal article, Aricept® is a blockbuster drug for the treatment of Alzheimer's disease.  And, as noted in Judge Ackerman's ruling, Aricept sales are a huge source of Eisai's revenue - "sales of Aricept® in the United States constitute 70% of Eisai’s...

(1) The US Court of Appeals for the Federal Circuit - in a complicated 22-page split Opinion earlier today Wed 19 Mar 2008 - provided Amgen another victory in its long patent battle(s) with Hoffmann-LaRoche. (2) Amgen's Aranesp® and EPOGEN® (each a prescription only product...

    Product shelf-life is a major economic concern for the agricultural industry.   The biological mechanism for regulating the ripening of fruits is mediated by ethylene.     Ethylene  management is addressed in three ways: 1) Ethylene...

I discuss this issue (and other FACTA-related issues) at length in my latest Liability Outlook.

The at-risk product launch by [NasdaqGS:TEVA] Teva of generic equivalents to [NYSE:PFE] Pfizer's Neurontin® (gabapentin) might - and the emphasis is clearly on might - yet prove to be an expensive mistake by Teva. The recent Opinion by the United States Court of Appeals for the Federal Circuit...

In my prior Tue 31 Jul 2007 Analysis available here http://news.glgroup.com/CM/Analysis/PostDetail.aspx?pid=14722 I stated: The upcoming Altace ® Opinion will most likely fall in line with this noted trend. In other words, King Pharmaceutical [NYSE:KG]'s patent protection for Altace ® (ramipril)...

With respect to the blockbuster antidepressant drug Lexapro®, the US Court of Appeals for the Federal Circuit, CAFC or Fed Cir, affirmed the prior November, 2006 Opinion of the Delaware District Court with respect to Plaintiff Forest Labs (NYSE:FRX) Paragraph (IV) patent infringement litigation...

It was expected that the Supreme Court's October Term 2006, which ended in June of this year, would result in decisions of great significance for the prospect of liability reform. But the surprise was that the greatest impact came not from the cases that immediately and directly raised issues...

KSR involved mechanical technologies, but its rulings apply to all different arts, including biotechnology, medical devices, and pharmaceuticals.  The applications of KSR analysis by the Federal Circuit are multiplying and the results are not in favor of patent owners, including those patent...

KSR is another in a series of anti-patent Supreme Court cases, including the recent eBay and Microsoft v. AT&T cases. Without doubt, these cases will make it harder to get patents through the U.S. Patent and Trademark Office and will make it easier to invalidate patents in court.  Patent "trolls"...